Q3 Earnings Forecast for Envista Issued By Leerink Partnrs
Equities researchers at Leerink Partnrs decreased their Q3 2025 EPS estimates for shares of Envista in a research report ...
Leerink Partners Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Outperform
Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...
Ex-Goldman Banker Advances Some Pay Claims Against Leerink Firm
An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied promised bonuses and deferred grant awards worth millions of dollars.
Hosted on MSN1d
Leerink Partners Downgrades Hologic (HOLX)
Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (NasdaqGS:HOLX) from Outperform to Market Perform. Analyst Price Forecast Suggests 20.21% Upside As of ...
Fintel on MSN2d
Leerink Partners Upgrades Regeneron Pharmaceuticals (REGN)
Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...
RBC Capital Reaffirms Their Buy Rating on Regeneron (REGN)
In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...
Thryv Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL
CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in the 2025 Leerink Partners ...
Acadia Healthcare: Undervalued Growth Potential Despite Conservative 2025 Guidance
Analyst Whit Mayo from Leerink Partners reiterated a Buy rating on Acadia Healthcare (ACHC – Research Report) and keeping the price target at ...